Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
9-ING-41
Cat. No.:
0225LY-0530
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
9-ING-41 serves as a specialized inhibitor of glycogen synthase kinase-3.
Synonym:
1034895-42-5; 9-ING-41; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; 3-(5-Fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
CAS No.:
1034895-42-5
Compound CID:
44582816
Formula:
C22H13FN2O5
Formula Weight:
404.35
Specification
Targets&IC50:
GSK-3β: 0.71 μM (IC50)
Relative Density:
1.63 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
9-ING-41 can be used in neurology and oncology research to explore the specific inhibition of glycogen synthase kinase-3 beta.
Library Information
Target:
GSK-3
Receptor:
GSK-3β
Pathways:
Autophagy; Stem cell regulation; Apoptosis; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-7
Plate Location:
h4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
125 mg/mL; 309.14 mM
